Moderna, Covid-19

Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.
Moderna Stock Jumps on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 billion for the third quarter.
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday note to investors said sales of the company’s respiratory syncytial virus vaccine mRESVIA was significantly lower than expected.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,
Moderna posts surprise profit as COVID vaccine sales exceed expectations
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of its COVID-19 vaccine.
Moderna, Pfizer or Novavax? How the three Covid-19 vaccines differ according to Yale Medicine
In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three vaccines available in the U.S.
Moderna Posts Unexpected Q3 Profit, Driven by Cost Cuts and Strong Covid Vaccine Sales
Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales. Moderna’s earnings per share and revenue surpassed Wall Street expectations, with earnings reaching a surprising profit and revenue exceeding projected figures.
Moderna swings to profits as new COVID shot powers Q3 beat
Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...
NBC News on MSN4d
Some people will need an extra Covid vaccine in the spring
In October, the Centers for Disease Control and Prevention recommended that high-risk adults get a second updated Covid ...
BioPharma Dive6h
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Business Insider1h
Moderna price target lowered to $62 from $75 at RBC Capital
RBC Capital lowered the firm’s price target on Moderna (MRNA) to $62 from $75 and keeps a Sector Perform rating on the shares following a COVID vaccine sale beat that was primarily driven by an ...
The Associated Press on MSN3h
Don't wait for a holiday surge. Now is a good time to get your flu and COVID-19 vaccines
Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to ...
Moderna Q3 2024 Preview: Revenue to fall due to continued COVID market share decline
Moderna (NASDAQ:MRNA) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market open. Analysts ...
Moderna is a ‘show-me story’ heading into Q3 earnings
Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...
Moderna’s Bancel steps down as sales chief, keeps CEO role
Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.